OptimizeRx Files Proxy Soliciting Material
Ticker: OPRX · Form: DEFA14A · Filed: Mar 11, 2025 · CIK: 1448431
| Field | Detail |
|---|---|
| Company | Optimizerx CORP (OPRX) |
| Form Type | DEFA14A |
| Filed Date | Mar 11, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, soliciting-material
TL;DR
OptimizeRx is sending out proxy materials, get ready for shareholder votes.
AI Summary
OptimizeRx Corporation is filing soliciting material under Rule 240.14a-12 for its Schedule 14A Proxy Statement. This filing is not a preliminary or definitive proxy statement but rather material used to solicit proxies. The company is incorporated in Nevada and its fiscal year ends on December 31st.
Why It Matters
This filing indicates OptimizeRx is actively engaging with shareholders regarding proxy matters, which could influence corporate governance and future company decisions.
Risk Assessment
Risk Level: low — This is a standard SEC filing for proxy solicitation, not indicating any immediate financial or operational risk.
Key Players & Entities
- OptimizeRx Corporation (company) — Registrant
- 240.14a-12 (legal_document) — Rule governing soliciting material
- Schedule 14A (legal_document) — Proxy Statement filing
FAQ
What type of filing is this Schedule 14A for OptimizeRx Corporation?
This Schedule 14A filing is classified as soliciting material under Rule 240.14a-12.
Is this a preliminary or definitive proxy statement?
No, this filing is specifically identified as soliciting material under § 240.14a-12, not a preliminary or definitive proxy statement.
Under which state is OptimizeRx Corporation incorporated?
OptimizeRx Corporation is incorporated in Nevada.
What is the fiscal year end for OptimizeRx Corporation?
The fiscal year end for OptimizeRx Corporation is December 31st.
What is the filing fee status for this document?
The filing indicates that no fee is required for this filing.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on March 11, 2025 regarding OptimizeRx Corp (OPRX).